Table 1. Difference in outpatient antimicrobial drug use DID in 21 European countries, 2004, and changes in use, 2000–2004*†.
| Substance class (ATC category) | Antimicrobial use, DIDs, 2004 |
Changes in antimicrobial drug use, 2000–2004 |
||||
|---|---|---|---|---|---|---|
| Maximum (country) | Minimum (country) | fd | >15% increase | >15% decrease | ||
| Total use (J01) | 33.4(GR) | 9.7 (NL) | 3.4 | HU, DK, GR, IE | BG, CZ, DE, FR | |
| Penicillins (J01C) | 12.8 (FR) | 3.4 (DE) | 3.8 | HU, DK | CZ, FR, DE, SK | |
| Cephalosporins, monobactams, carbapenems (J01D) | 7.2 (GR) | 0.05 (NL) | >100 | SI | BE, BG, CZ, FR, IS NL, ES, SE | |
| Macrolides, lincosamines, streptogramins (J01F) | 9.9 (GR) | 0.8 (BG) | 12.4 | BG, HR, GR, IE, NL | BE, FR, DE, LU, ES | |
| Fluoroquinolones (J01MA) | 3.04 (PT) | 0.28 (DK) | 10.9 | AT, BG, CZ, DK, FI, DE, HU, IE, LU, UK | SI | |
*DID, defined daily dose/1,000 inhabitants; ATC, Anatomic Therapeutic Chemical classification; fd, factor difference. †Country designations: AT, Austria; BE, Belgium; BG, Bulgaria; CZ, Czech Republic; DE, Germany; DK, Denmark; ES, Spain; FI, Finland; FR, France; GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; LU, Luxembourg; NL, the Netherlands; PT, Portugal; SE, Sweden; SI, Slovenia; SK, Slovakia; UK, United Kingdom.